Cargando…
Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
PURPOSE: This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: From August 2009 t...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473261/ https://www.ncbi.nlm.nih.gov/pubmed/30121968 http://dx.doi.org/10.4143/crt.2018.250 |
_version_ | 1783412389559926784 |
---|---|
author | Wang, Lei Wu, Zheng Xie, Dehuan Zeng, Ruifang Cheng, Wanqin Hu, Jiang Huang, Shaomin Zhou, Shu Zhong, Rui Su, Yong |
author_facet | Wang, Lei Wu, Zheng Xie, Dehuan Zeng, Ruifang Cheng, Wanqin Hu, Jiang Huang, Shaomin Zhou, Shu Zhong, Rui Su, Yong |
author_sort | Wang, Lei |
collection | PubMed |
description | PURPOSE: This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: From August 2009 to August 2013, patients with stage III–IVB NPC were treated with IC and concurrent chemoradiotherapy. Gross tumor volume of nasopharynx (GTVnx)–residual and gross tumor volume of cervical lymph node (GTVnd)–residual were contoured according to post-IC residual primary tumor and any N+ disease, respectively. The tumor regression field was included in CTVnx1/CTVnd1 and prescribed a dose of 60 Gy. Outcomes and toxicities of all patients were evaluated. RESULTS: A total of 57 patients were enrolled. At a median follow-up of 68 months, three cases displayed locoregional recurrence and one case showed both distant metastasis and locoregional recurrence. All locoregional recurrences were in the GTVnx-residual/GTVnd-residual and in-field. The 5-year overall, locoregional relapse-free, distant metastasis-free, and progression-free survival rates were 82.2%, 87.7%, 85.8% and 80.3%, respectively. CONCLUSION: After IC, contouring of GTVnx-residual/GTVnd-residual as residual tumor volume and distribution 60 Gy ofradiation dose to the tumorregression field may be feasible and need further investigation. |
format | Online Article Text |
id | pubmed-6473261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-64732612019-04-26 Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Wang, Lei Wu, Zheng Xie, Dehuan Zeng, Ruifang Cheng, Wanqin Hu, Jiang Huang, Shaomin Zhou, Shu Zhong, Rui Su, Yong Cancer Res Treat Original Article PURPOSE: This study aims to investigate the feasibility of contouring target volume according to residual tumor and decreasing the dose to the tumor regression field after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (NPC). MATERIALS AND METHODS: From August 2009 to August 2013, patients with stage III–IVB NPC were treated with IC and concurrent chemoradiotherapy. Gross tumor volume of nasopharynx (GTVnx)–residual and gross tumor volume of cervical lymph node (GTVnd)–residual were contoured according to post-IC residual primary tumor and any N+ disease, respectively. The tumor regression field was included in CTVnx1/CTVnd1 and prescribed a dose of 60 Gy. Outcomes and toxicities of all patients were evaluated. RESULTS: A total of 57 patients were enrolled. At a median follow-up of 68 months, three cases displayed locoregional recurrence and one case showed both distant metastasis and locoregional recurrence. All locoregional recurrences were in the GTVnx-residual/GTVnd-residual and in-field. The 5-year overall, locoregional relapse-free, distant metastasis-free, and progression-free survival rates were 82.2%, 87.7%, 85.8% and 80.3%, respectively. CONCLUSION: After IC, contouring of GTVnx-residual/GTVnd-residual as residual tumor volume and distribution 60 Gy ofradiation dose to the tumorregression field may be feasible and need further investigation. Korean Cancer Association 2019-04 2018-08-13 /pmc/articles/PMC6473261/ /pubmed/30121968 http://dx.doi.org/10.4143/crt.2018.250 Text en Copyright © 2019 by the Korean Cancer Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Wang, Lei Wu, Zheng Xie, Dehuan Zeng, Ruifang Cheng, Wanqin Hu, Jiang Huang, Shaomin Zhou, Shu Zhong, Rui Su, Yong Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
title | Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
title_full | Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
title_fullStr | Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
title_full_unstemmed | Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
title_short | Reduction of Target Volume and the Corresponding Dose for the Tumor Regression Field after Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma |
title_sort | reduction of target volume and the corresponding dose for the tumor regression field after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473261/ https://www.ncbi.nlm.nih.gov/pubmed/30121968 http://dx.doi.org/10.4143/crt.2018.250 |
work_keys_str_mv | AT wanglei reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT wuzheng reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT xiedehuan reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT zengruifang reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT chengwanqin reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT hujiang reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT huangshaomin reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT zhoushu reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT zhongrui reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma AT suyong reductionoftargetvolumeandthecorrespondingdoseforthetumorregressionfieldafterinductionchemotherapyinlocoregionallyadvancednasopharyngealcarcinoma |